ProCE Banner Activity

Aggressive B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Slideset Download
Download these expert-selected slides on aggressive B-cell lymphomas to help diagnose and manage your patients with DLBCL and MCL.

Released: March 08, 2022

Expiration: March 07, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Genmab US Inc and AbbVie

Karyopharm Therapeutics

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consulting fees from AbbVie, Bayer, Celgene, EMD Serono, Genentech, Janssen, Karyopharm, and Kite.

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees paid to his institution from AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Gilead Sciences, Great Point Partners, Hutchison MediPharma, Iksuda, Janssen, Juno, Kite, MorphoSys, Novartis, Nurix, Pharmacyclics, Roche, Seattle Genetics, Servier, Takeda, TG Therapeutics, Unum, Verastem, Vincerx, and Yingli and funds for reseach support paid to his insitution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp, Unum, and Verastem.